Update on Emerging HIV Drug Resistance to Integrase Inhibitors - How Concerned Should We Be?

Join this comprehensive webinar panel discussion examining the critical issue of emerging HIV drug resistance to integrase inhibitors, particularly dolutegravir (DTG), and its implications for global HIV treatment strategies. Learn about the World Health Organization's 2019 recommendation to use DTG in first- and second-line antiretroviral therapy regimens based on its superior effectiveness, tolerability, and lower resistance profile compared to other drugs. Explore how 110 resource-limited countries adopted DTG-based treatments by 2021, with approximately 22 million people receiving this therapy. Examine recent concerning survey data revealing emerging DTG resistance levels, with particular focus on findings from African countries where this issue is most prevalent. Understand the public health and individual health implications of developing resistance to what was considered a highly effective treatment option. Gain insights from leading HIV drug resistance experts including Leonard Kingwara, Francois Venter, Bilaal Wilson Matola, and moderator Obiageli Okafor as they discuss evidence-based strategies for combating emerging resistance patterns. Discover lessons learned from current resistance surveillance efforts and explore approaches to preserve the efficacy of available antiretroviral therapies. Participate in live Q&A sessions to address specific concerns about HIV drug resistance management and treatment optimization in various clinical settings.